VolitionRx (NYSE:VNRX) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

Several other research firms have also recently issued reports on VNRX. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a research report on Tuesday, June 10th. Wall Street Zen assumed coverage on VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating on the stock. Finally, HC Wainwright assumed coverage on VolitionRx in a research report on Tuesday, April 8th. They set a "buy" rating and a $2.50 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $3.50.

VolitionRx Trading Up 2.9%

Shares of VNRX traded up $0.02 during mid-day trading on Wednesday, hitting $0.68. 91,836 shares of the company's stock were exchanged, compared to its average volume of 207,269. VolitionRx has a fifty-two week low of $0.40 and a fifty-two week high of $0.94. The firm has a market capitalization of $70.71 million, a P/E ratio of -1.89 and a beta of 1.20. The business's 50 day moving average is $0.61 and its two-hundred day moving average is $0.58.

Hedge Funds Weigh In On VolitionRx

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lagoda Investment Management L.P. lifted its holdings in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of VolitionRx in the fourth quarter valued at about $36,000. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after purchasing an additional 60,209 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the fourth quarter valued at about $29,000. Finally, Northern Trust Corp lifted its holdings in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.